Clinical Trials
23 trialsNCT06312137 2026-05-22
TroFuse-019
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06417814 2026-05-14
TROPION-Lung15
AstraZeneca
Phase 3 Recruiting
NCT07538193 2026-04-20
Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
Tang-Du Hospital
Phase NA Not yet recruiting
NCT05261399 2026-04-06
SAFFRON
AstraZeneca
Phase 3 Active not recruiting
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT03976323 2026-02-25
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT03519971 2025-10-28
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT04035486 2025-10-10
FLAURA2
AstraZeneca
Phase 3 Active not recruiting
NCT06463665 2025-09-26
VIRO-25
Genelux Corporation
Phase 2 Recruiting
NCT02185690 2025-08-21
MEK162
University Health Network, Toronto
Phase 1 Completed
NCT03800134 2025-06-11
AEGEAN
AstraZeneca
Phase 3 Active not recruiting
NCT05241873 2025-02-10
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
Phase 1 Terminated
NCT04816214 2024-03-05
GEOMETRY-E
Novartis
Phase 3 Terminated
NCT03952403 2023-08-08
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Shanghai Henlius Biotech
Phase 3 Unknown
NCT05153408 2023-06-18
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT02367781 2021-08-09
IMpower130
Hoffmann-La Roche
Phase 3 Completed
NCT02259582 2020-09-09
DENALI
Mereo BioPharma
Phase 2 Completed
NCT01139775 2018-05-18
A Study in Non Small Cell Lung Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT00506051 2016-08-25
ZD6474(Vandetanib) + Alimta Combo Study
Sanofi
Phase 1 Completed
NCT00589667 2014-04-02
A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00365183 2013-10-31
Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
Pharmacyclics LLC.
Phase 2 Terminated
NCT00191308 2011-10-21
Molecular Profiling in Lung Cancer Patients
Eli Lilly and Company
Phase 2 Completed